+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a new treatment approach for people with metastatic pancreatic ductal adenocarcinoma PDAC who have progressed after initial therapy with certain chemotherapy combinations. The study focuses on assessing the safety, tolerability, and overall survival when adding an experimental therapy called E-EDV-D682GC to standard chemotherapy drugs gemcitabine and nab-paclitaxel. This trial is a randomized, blinded Phase IIIa study designed to compare this combination against gemcitabine and nab-paclitaxel alone. The experimental treatment includes two investigational products E-EDV-D682, which packages a chemotherapy agent targeted to cancer cells expressing EGFR, and EDV-GC, which aims to boost the bodys immune response. Participants receive these drugs alongside gemcitabine and nab-paclitaxel. The trial has two parts an initial safety phase with at least six participants receiving the experimental combination to check for side effects, followed by a randomized phase where participants are assigned either to the experimental combination or to standard chemotherapy with placebo. Treatment cycles involve bi-weekly then weekly visits, with tumor assessments every 8 weeks to monitor response. Participants will be involved for about six months, including screening, treatment, and follow-up. They will undergo regular clinical visits, imaging scans to measure tumor burden, and safety assessments throughout the study and for up to 30 days after treatment ends. Researchers will monitor adverse events and overall survival, as well as measure disease progression and response using established imaging criteria. The study also includes a safety follow-up period to closely track participants health after treatment.

Age: 18Years +All GendersPhase 1Phase 2
4 locations
P

Actively Recruiting

Researchers are evaluating the safety and preliminary effectiveness of a combination treatment involving M-CENK adoptive cell therapy, N-803, and gemcitabine in women with platinum-resistant high-grade ovarian cancer. This phase 2, single-arm study focuses on participants whose cancer has returned despite previous platinum-based chemotherapy and other therapies including bevacizumab and, if applicable, PARP inhibitors. The study aims to understand how this combination affects disease progression and survival. Participants will undergo a blood collection procedure called apheresis to gather cells needed to create M-CENK therapy. Treatment starts with gemcitabine given intravenously on specific days in 4-week cycles. From the second cycle onward, participants will also receive M-CENK cell infusions intravenously and N-803 injections under the skin. N-803 dosing continues with additional doses spaced two weeks apart after the last M-CENK infusion. Treatment continues until M-CENK cells are no longer available or disease progression is confirmed, unless the investigator believes the participant is still benefiting. During the study, participants are closely monitored through regular assessments including imaging to evaluate tumor response and progression. Safety is evaluated through laboratory tests, vital signs, and tracking adverse events. After completing or stopping treatment, participants will be followed every 12 weeks for up to one year to monitor survival and disease status. The study measures several outcomes such as progression-free survival, overall survival, response rates, and disease control, assessing the impact of the combined therapies over time.

Age: 18Years - 85YearsFEMALEPhase 2
2 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of Anktiva, also known as Nogapendekin Alfa Inbakicept NAI, for treating individuals with Long COVID-19. Long COVID is defined as ongoing symptoms that persist after the initial COVID-19 infection has resolved. This Phase 2 trial aims to evaluate how participants respond to this treatment and assess any associated risks. Participants will receive 600 micrograms of Anktiva administered as a subcutaneous injection. The study follows a single-group design, where all enrolled participants receive the investigational drug. The treatment period lasts approximately 75 days, during which safety and vital signs will be closely monitored. The study focuses on recording any adverse events and changes in laboratory tests during and shortly after treatment. During the trial, participants will undergo regular assessments including blood tests to monitor lymphocyte counts, vital signs such as temperature, heart rate, blood pressure, respiratory rate, and oxygen saturation. The research team will track any treatment-related side effects through 30 days after the last dose. Participants are expected to comply with study visits and evaluations throughout the treatment period and follow-up to help understand the treatments safety profile and impact on Long COVID symptoms.

Age: 18Years - 70YearsAll GendersPhase 2
1 location
C

Actively Recruiting

Researchers are conducting a randomized, open-label phase 3 clinical trial to compare treatments for adults with advanced or metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitor therapy. The study focuses on two groups one receiving N-803 plus tislelizumab and docetaxel, and the other having previously failed immune checkpoint inhibitor therapy combined with docetaxel. The trial aims to evaluate the effectiveness and safety of these treatments compared to docetaxel alone. Participants are assigned to two cohorts and randomized in a 21 ratio to either the experimental treatment or control arm. Cohort A receives N-803, tislelizumab, and docetaxel during the first two 3-week cycles, followed by N-803 and tislelizumab until the study ends. Cohort B receives N-803, their prior failed checkpoint inhibitor, and docetaxel in the first two cycles, then N-803 and the prior checkpoint inhibitor thereafter. Control arms for both cohorts receive docetaxel monotherapy in repeated 3-week cycles. During the study, participants undergo treatment cycles every three weeks with scheduled administration of drugs via subcutaneous injection or intravenous infusion. Researchers will assess overall survival approximately 12 months after treatment begins. Participants must attend study visits and follow-ups as required. Safety and treatment effects will be monitored throughout the trial, which is expected to continue until January 2029.

Age: 18Years - 90YearsAll GendersPhase 3
49 locations
P

Actively Recruiting

Researchers are conducting a first-in-human, multicenter, open-label Phase 12 study to evaluate AT-1965 in patients with advanced, refractory, or recurrent solid tumors, including metastatic triple-negative breast cancer. The study aims to identify the maximum tolerated dose or recommended Phase 2 dose of AT-1965 and to assess dose limiting toxicities, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. Participants will receive AT-1965 Liposome Injection administered intravenously once weekly on Days 1, 8, and 15 of each 28-day treatment cycle. The study consists of a dose escalation phase to determine safe dosing followed by a dose expansion phase to further evaluate the treatment in a larger group. Treatment cycles repeat every 28 days, with dosing and assessments continuing as per protocol. During the study, participants will undergo safety monitoring, pharmacokinetic and pharmacodynamic testing, and tumor assessments using RECIST criteria at 3, 6, and 9 months. Adverse events and serious adverse events will be tracked from consent through 30 days after the last dose. Laboratory tests and clinical evaluations occur regularly during treatment cycles. The total participation duration varies, with ongoing safety and efficacy evaluations throughout the study period.

Age: 18Years +All GendersPhase 1Phase 2
9 locations